Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CFO Purchases 9,391 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson acquired 9,391 shares of Sensei Biotherapeutics stock in a transaction that occurred on Wednesday, June 24th. The shares were purchased at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the purchase, the chief financial officer directly owned 26,804 shares in the company, valued at $700,388.52. The trade was a 53.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sensei Biotherapeutics Stock Performance

NASDAQ FTH traded down $1.80 during trading on Friday, reaching $22.87. 145,732 shares of the stock traded hands, compared to its average volume of 82,691. Sensei Biotherapeutics, Inc. has a fifty-two week low of $6.32 and a fifty-two week high of $36.76.

Analyst Ratings Changes

Several equities analysts have recently issued reports on FTH shares. Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a report on Friday. They issued an “outperform” rating and a $57.00 price target for the company. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. HC Wainwright assumed coverage on Sensei Biotherapeutics in a report on Monday. They set a “buy” rating and a $60.00 target price on the stock. Finally, Weiss Ratings started coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.